drugset
drugset / Trial / NCT05579860

A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healthy Adult Participants

NCT05579860 ↗

Phase 1 Completed 104 enrolled Ionis Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelOther

Summary

The purpose of the study is to assess the bioequivalence of olezarsen between 2 subcutaneous (SC) formulations \[(autoinjector (AI) and vial\] at 2 dose levels in healthy adult participants.

Timeline

Start
2022-10-05
Primary completion
2023-05-22
Completion
2023-05-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Olezarsen Antisense oligonucleotide 50 mg Subcutaneous
Subject Olezarsen Antisense oligonucleotide 80 mg Subcutaneous

Indications

No indication recorded.